

Christoph Roderburg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3070373/publications.pdf>

Version: 2024-02-01

122
papers

4,727
citations

117571

34
h-index

106281

65
g-index

124
all docs

124
docs citations

124
times ranked

7306
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibiotic therapy is associated with an increased incidence of cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1285-1293.	1.2	3
2	Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1411-1416.	1.2	3
3	Prevalence of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3471-3471.	1.1	1
4	An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 247-248.	1.8	25
5	Authors' reply: Pulmonary hypertension is associated with an increased incidence of NAFLD. <i>Journal of Internal Medicine</i> , 2022, 291, 527-527.	2.7	0
6	A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS485-TPS485.	0.8	1
7	Autoimmune disorders are positively associated with achalasia. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14327.	1.6	0
8	The fecal mycobiome in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 788-799.	1.8	66
9	Overweight and Obesity Determine the Risk for Gastrointestinal Cancer in a Sex-Dependent Manner: A Retrospective Cohort Study of 287,357 Outpatients in Germany. <i>Cancers</i> , 2022, 14, 931.	1.7	14
10	The spectrum of comorbidities at the initial diagnosis of heart failure a case control study. <i>Scientific Reports</i> , 2022, 12, 2670.	1.6	8
11	Obesity and lipid metabolism disorders determine the risk for development of long COVID syndrome: a cross-sectional study from 50,402 COVID-19 patients. <i>Infection</i> , 2022, 50, 1165-1170.	2.3	31
12	N, LNR or LODDS: Which Is the Most Appropriate Lymph Node Classification Scheme for Patients with Radically Resected Pancreatic Cancer?. <i>Cancers</i> , 2022, 14, 1834.	1.7	7
13	Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 68.	1.7	2
14	Prevalence of diabetes mellitus among 80,193 gastrointestinal cancer patients in five European and three Asian countries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1057-1062.	1.2	11
15	Low blood levels of high-density lipoprotein (HDL) cholesterol are positively associated with cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3039-3046.	1.2	16
16	An Elevated FIB-4 Score Is Associated with an Increased Incidence of Depression among Outpatients in Germany. <i>Journal of Clinical Medicine</i> , 2022, 11, 2214.	1.0	3
17	An elevated FIB-4 score is not associated with cardiovascular events: a longitudinal analysis from 137 842 patients with and without chronic liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, .	0.8	2
18	Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2235-2246.	1.2	3

#	ARTICLE	IF	CITATIONS
19	An elevated FIB-4 score is associated with an increased incidence of liver cancer: A longitudinal analysis among 248,224 outpatients in Germany. <i>European Journal of Cancer</i> , 2022, 168, 41-50.	1.3	0
20	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. <i>Neuroendocrinology</i> , 2021, 111, 217-236.	1.2	17
21	Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis. <i>JGH Open</i> , 2021, 5, 356-363.	0.7	0
22	From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1492.	1.8	16
23	Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC. <i>PLoS ONE</i> , 2021, 16, e0247917.	1.1	9
24	Achalasia is associated with a higher incidence of depression in outpatients in Germany. <i>PLoS ONE</i> , 2021, 16, e0250503.	1.1	11
25	Combined analysis of gut microbiota, diet and <i>PNPLA3</i> polymorphism in biopsy-proven non-alcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 1576-1591.	1.9	11
26	Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002243.	1.2	9
27	Diverticular disease is associated with an increased incidence rate of depression and anxiety disorders. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2437-2443.	1.0	2
28	Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6569.	1.8	3
29	Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies. <i>Clinical and Translational Science</i> , 2021, 14, 1853-1863.	1.5	6
30	Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 3907.	1.0	17
31	The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8569.	1.8	8
32	Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer—a case series. <i>PLoS ONE</i> , 2021, 16, e0255983.	1.1	4
33	Perioperative rifaximin is not associated with enhanced functional and volumetric recovery after major liver resection. <i>Scientific Reports</i> , 2021, 11, 17936.	1.6	1
34	Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Cancers</i> , 2021, 13, 4463.	1.7	2
35	PD-L1 “inhibitors in neuroendocrine neoplasia. <i>Medicine (United States)</i> , 2021, 100, e23835.	0.4	7
36	Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany. <i>Cancers</i> , 2021, 13, 408.	1.7	90

#	ARTICLE	IF	CITATIONS
37	Sarcopenia Predicts Cancer Mortality in Male but Not in Female Patients Undergoing Surgery for Cholangiocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5359.	1.7	5
38	Faecal Micro-RNAs in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 110-117.	0.6	30
39	Evaluating hepatotoxic effects of chemotherapeutic agents with gadoxetic-acid-enhanced magnetic resonance imaging. <i>European Journal of Radiology</i> , 2020, 124, 108807.	1.2	2
40	In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4993.	1.8	8
41	Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0239386.	1.1	11
42	Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2881.	1.0	8
43	Skeletal Muscle Composition Predicts Outcome in Critically Ill Patients. , 2020, 2, e0171.		34
44	Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. <i>Cancers</i> , 2020, 12, 3826.	1.7	11
45	A case report of an excellent response to interferon- β in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. <i>Medicine (United States)</i> , 2020, 99, e20820.	0.4	1
46	Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1647.	1.0	6
47	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. <i>Hepatic Oncology</i> , 2020, 7, HEP20.	4.2	30
48	The role of the innate immune system in the development and treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2020, 7, HEP17.	4.2	46
49	Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer. <i>JHEP Reports</i> , 2020, 2, 100080.	2.6	17
50	Current status of immunotherapy in gastrointestinal malignancies. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 542-555.	0.2	5
51	Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1969-1977.	1.4	27
52	Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. <i>Cancers</i> , 2020, 12, 733.	1.7	17
53	Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. <i>PLoS ONE</i> , 2020, 15, e0244504.	1.1	3
54	Pulmonary complications in patients with liver cirrhosis. <i>Journal of Translational Internal Medicine</i> , 2020, 8, 150-158.	1.0	19

#	ARTICLE	IF	CITATIONS
55	A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 14, 20.	0.4	4
56	Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3049.	1.8	110
57	A Combined Score of Circulating miRNAs Allows Outcome Prediction in Critically Ill Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1644.	1.0	6
58	Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies. <i>Cancers</i> , 2019, 11, 1503.	1.7	35
59	The Role of Adipokines as Circulating Biomarkers in Critical Illness and Sepsis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4820.	1.8	16
60	Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0210944.	1.1	43
61	The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1468-1478.	0.5	50
62	miR-155 Predicts Long-Term Mortality in Critically Ill Patients Younger than 65 Years. <i>Mediators of Inflammation</i> , 2019, 2019, 1-8.	1.4	12
63	Prognostic Relevance of Altered Lymphocyte Subpopulations in Critical Illness and Sepsis. <i>Journal of Clinical Medicine</i> , 2019, 8, 353.	1.0	49
64	Treatment Strategies for Hepatocellular Carcinoma – a Multidisciplinary Approach. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1465.	1.8	158
65	Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma. <i>Scientific Reports</i> , 2019, 9, 1489.	1.6	5
66	High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. <i>Carcinogenesis</i> , 2019, 40, 947-955.	1.3	19
67	Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. <i>Visceral Medicine</i> , 2019, 35, 43-46.	0.5	6
68	Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer. <i>Disease Markers</i> , 2019, 2019, 1-8.	0.6	7
69	Serum Levels of miR-143 Predict Survival in Critically Ill Patients. <i>Disease Markers</i> , 2019, 2019, 1-10.	0.6	10
70	Soluble urokinase plasminogen activator receptor (suPAR) as a novel biomarker in patients undergoing resection of pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 248-248.	0.8	0
71	Reply to: “Osteopontin a promising prognostic biomarker for cholangiocarcinoma?” <i>Journal of Hepatology</i> , 2018, 68, 206-207.	1.8	0
72	Circulating Levels of Osteopontin Predict Patients’ Outcome after Resection of Colorectal Liver Metastases. <i>Journal of Clinical Medicine</i> , 2018, 7, 390.	1.0	12

#	ARTICLE	IF	CITATIONS
73	microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis. <i>Gastroenterology</i> , 2018, 155, 1951-1966.e26.	0.6	86
74	Serum levels of kisspeptin are elevated in critically ill patients. <i>PLoS ONE</i> , 2018, 13, e0206064.	1.1	8
75	A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 805.	1.6	20
76	Circulating Biomarkers for Cholangiocarcinoma. <i>Digestive Diseases</i> , 2018, 36, 281-288.	0.8	18
77	Elevated Serum Levels of Mixed Lineage Kinase Domain-Like Protein Predict Survival of Patients during Intensive Care Unit Treatment. <i>Disease Markers</i> , 2018, 2018, 1-8.	0.6	16
78	Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 175.	1.0	5
79	Elevated serum levels of bone sialoprotein during ICU treatment predict long-term mortality in critically ill patients. <i>Scientific Reports</i> , 2018, 8, 9750.	1.6	3
80	The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. <i>International Journal of Molecular Sciences</i> , 2018, 19, 261.	1.8	96
81	IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1766.	1.8	38
82	Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases. <i>Oncotarget</i> , 2018, 9, 27027-27038.	0.8	19
83	Soluble urokinase plasminogen activator receptor (suPAR) as a novel serum biomarker for patients undergoing resection of colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, 309-309.	0.8	0
84	Soluble urokinase plasminogen activator receptor (suPAR) as a serum biomarker for patients undergoing resection of pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16203-e16203.	0.8	0
85	Current and future biomarkers for pancreatic adenocarcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831769223.	0.8	62
86	RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. <i>Cancer Cell</i> , 2017, 31, 94-109.	7.7	115
87	CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. <i>Scientific Reports</i> , 2017, 7, 16975.	1.6	65
88	miR-1224 inhibits cell proliferation in acute liver failure by targeting the antiapoptotic gene Nfib. <i>Journal of Hepatology</i> , 2017, 67, 966-978.	1.8	64
89	miR-223 represents a biomarker in acute and chronic liver injury. <i>Clinical Science</i> , 2017, 131, 1971-1987.	1.8	35
90	Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 67, 749-757.	1.8	64

#	ARTICLE	IF	CITATIONS
91	A liver nodule in a patient transplanted for primary sclerosing cholangitis: an interdisciplinary diagnostic approach. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 56-62.	0.2	3
92	Cell-specific functions of miRNA in the liver. <i>Journal of Hepatology</i> , 2017, 66, 655-656.	1.8	14
93	Role of circulating microRNAs in liver diseases. <i>World Journal of Hepatology</i> , 2017, 9, 586.	0.8	60
94	Elevated Omentin Serum Levels Predict Long-Term Survival in Critically Ill Patients. <i>Disease Markers</i> , 2016, 2016, 1-9.	0.6	12
95	miR-122 expression is not regulated during activation of hepatic stellate cells. <i>Journal of Hepatology</i> , 2016, 65, 865-867.	1.8	4
96	Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma. <i>Clinical and Translational Medicine</i> , 2016, 5, 39.	1.7	14
97	Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis. <i>Visceral Medicine</i> , 2016, 32, 121-126.	0.5	14
98	Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury. <i>Clinical Science</i> , 2016, 130, 1197-1207.	1.8	59
99	IKK β kinase β control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell death mediator receptor-interacting protein kinase 1. <i>Hepatology</i> , 2016, 64, 1217-1231.	3.6	54
100	The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance. <i>Nature Communications</i> , 2016, 7, 11869.	5.8	68
101	Serum Levels of TNF Receptor Ligands Are Dysregulated in Sepsis and Predict Mortality in Critically Ill Patients. <i>PLoS ONE</i> , 2016, 11, e0153765.	1.1	15
102	miR-30c and miR-193 are a part of the TGF β -dependent regulatory network controlling extracellular matrix genes in liver fibrosis. <i>Journal of Digestive Diseases</i> , 2015, 16, 513-524.	0.7	57
103	Persistently elevated osteopontin serum levels predict mortality in critically ill patients. <i>Critical Care</i> , 2015, 19, 271.	2.5	40
104	Circulating MicroRNA-223 Serum Levels Do Not Predict Sepsis or Survival in Patients with Critical Illness. <i>Disease Markers</i> , 2015, 2015, 1-10.	0.6	34
105	Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. <i>Liver International</i> , 2015, 35, 1172-1184.	1.9	98
106	The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 24-33.	0.7	45
107	Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. <i>Journal of Hepatology</i> , 2014, 61, 1434-1437.	1.8	99
108	A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. <i>EMBO Molecular Medicine</i> , 2014, 6, 1062-1074.	3.3	253

#	ARTICLE	IF	CITATIONS
109	Levels of Circulating miR-133a Are Elevated in Sepsis and Predict Mortality in Critically Ill Patients. <i>Critical Care Medicine</i> , 2014, 42, 1096-1104.	0.4	111
110	The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. <i>Gut Microbes</i> , 2014, 5, 441-445.	4.3	66
111	Serum concentrations of A Proliferation-Inducing Ligand (APRIL) are elevated in sepsis and predict mortality in critically ill patients. <i>Journal of Critical Care</i> , 2013, 28, 882.e1-882.e11.	1.0	10
112	miR-133a mediates TGF- β 2-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. <i>Journal of Hepatology</i> , 2013, 58, 736-742.	1.8	110
113	U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. <i>Experimental and Molecular Medicine</i> , 2013, 45, e42-e42.	3.2	139
114	Circulating MicroRNA-150 Serum Levels Predict Survival in Patients with Critical Illness and Sepsis. <i>PLoS ONE</i> , 2013, 8, e54612.	1.1	138
115	TNF-Dependent Signaling Pathways in Liver Cancer: Promising Targets for Therapeutic Strategies?. <i>Digestive Diseases</i> , 2012, 30, 500-507.	0.8	16
116	Micro-RNA Profiling in Human Serum Reveals Compartment-Specific Roles of miR-571 and miR-652 in Liver Cirrhosis. <i>PLoS ONE</i> , 2012, 7, e32999.	1.1	92
117	Safe Use of FOLFOX in Two Patients With Metastatic Colorectal Carcinoma and Severe Hepatic Dysfunction. <i>Clinical Colorectal Cancer</i> , 2011, 10, E6-E9.	1.0	8
118	Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. <i>Hepatology</i> , 2011, 53, 209-218.	3.6	696
119	MicroRNA-199a/b-3p: A new star in the liver microcosmos. <i>Hepatology</i> , 2011, 54, 729-731.	3.6	7
120	Obesity and liver cancer: A key role for interleukin-6 and signal transducer and activator of transcription 3?. <i>Hepatology</i> , 2010, 51, 1850-1852.	3.6	7
121	Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma?. <i>Oncotarget</i> , 2010, 1, 373-378.	0.8	43
122	Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib. <i>World Journal of Hepatology</i> , 2010, 2, 239.	0.8	3